Skip to main content
FDA breakthrough therapy status granted to Proteostasis' cystic fibrosis drug

The FDA gave therapy status to Proteostasis Therapeutics' PTI-428, which is being developed as a treatment for patients with cystic fibrosis who have two copies of the F508del genetic mutation and are currently receiving treatment with Vertex Pharmaceuticals' Orkambi, or lumacaftor/ivacaftor.

Full Story: